's clinical development plans and the potential for
vicriviroc. Forward-looking statements relate to expectations or forecasts
of future events. Schering-Plough does not assume the obligation to update
any forward-looking statement. Many factors could cause actual results to
differ materially from Schering-Plough's forward-looking statements,
including market forces, economic factors, product availability, patent and
other intellectual property protection, current and future branded, generic
or over-the-counter competition, the regulatory process, and any
developments following regulatory approval, among other uncertainties. For
further details about these and other factors that may impact the
forward-looking statements, see Schering- Plough's Securities and Exchange
Commission filings, including Part I, Item 1A. "Risk Factors" in
Schering-Plough's 2007 10-K/A.
1 Hoffmann C (2007) The epidemiology of HIV coreceptor tropism. Eur J Med
Res (2007) 12: 385-390.
2 Atazanavir sulfate is a Bristol-Myers Squibb Company prescription
medicine. Please see the atazanavir product insert for information on
3 Truvada is a registered trademark of Gilead Sciences, Inc. Please see
the Truvada product insert for information on this product.
4 Vicriviroc, a next generation CCR5 antagonist, exhibits potent,
sustained suppression of viral replication in treatment-experienced
adults: VICTOR-E1 48-week results (39LB); 15th Conference on
Retroviruses and Opportunistic Infections (CROI); February 2008; Boston.
5 ACTG 5211: Phase II study of the safety and efficacy of vicriviroc (VCV)
in HIV-infected treatment-experienced subjects: 48 week results
(TUAB102); International AIDS Society 4th IAS Conference on HIV
Pathogenesis, Treatment and Prevention; July 2007; Sydney, Australia.
6 Hammer SM, Schechter M, Montaner JS, et al. Treatment for
Page: 1 2 3 4 5 6 Related medicine technology :1
|SOURCE Schering-Plough Corporation|
Copyright©2008 PR Newswire.
All rights reserved
. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation2
. Schering-Plough Reports Top-Line Results of the IDEAL Study3
. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA4
. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting5
. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate6
. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients7
. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type8
. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer9
. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia10
. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update11
. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging